LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

Search

Axsome Therapeutics Inc

Fechado

SetorSaúde

108.04 -1.66

Visão Geral

Variação de preço das ações

24h

Atual

Mín

107.52

Máximo

111

Indicadores-chave

By Trading Economics

Rendimento

15M

-59M

Vendas

2.7M

121M

EPS

-1.216

Margem de lucro

-48.914

Funcionários

712

EBITDA

14M

-57M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+63.56% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-62M

5.4B

Abertura anterior

109.7

Fecho anterior

108.04

Sentimento de Notícias

By Acuity

24%

76%

50 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Axsome Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de jun. de 2025, 22:03 UTC

Grandes Movimentos do Mercado

Gamestop Shares Fall After Company Plans Convertible Notes Offering

11 de jun. de 2025, 20:51 UTC

Ganhos

Oracle Shares Jump as CEO Targets 'Dramatically Higher' Revenue Growth Ahead

11 de jun. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Decline on Tariff Uncertainty, Stronger Yen -- Market Talk

11 de jun. de 2025, 23:39 UTC

Conversa de Mercado

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

11 de jun. de 2025, 22:16 UTC

Ganhos

Oracle Shares Jump With Target for Major Revenue Gains Ahead -- Update

11 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

11 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

11 de jun. de 2025, 20:27 UTC

Ganhos

Chime Gets Set to Debut as IPO Market Starts to Heat Up -- Barrons.com

11 de jun. de 2025, 20:27 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 de jun. de 2025, 20:10 UTC

Ganhos

Oracle Expects Triple-Digit MultiCloud Rev Growth to Continue in FY26 >ORCL

11 de jun. de 2025, 20:09 UTC

Ganhos

Oracle: Cloud Infrastructure Growth Rate Is Expected to Increase From 50% in FY25 to Over 70% in FY26 >ORCL

11 de jun. de 2025, 20:08 UTC

Ganhos

Oracle Expects Total Cloud Growth Rate--Applications Plus Infrastructure--Will Increase From 24% in FY25 to Over 40% in FY26 >ORCL

11 de jun. de 2025, 20:08 UTC

Ganhos

Oracle Sees Revenue Growth Rates 'Dramatically Higher' in FY26 >ORCL

11 de jun. de 2025, 20:08 UTC

Ganhos

Oracle 4Q Non-GAAP Operating Income Was $7 B >ORCL

11 de jun. de 2025, 20:08 UTC

Ganhos

Oracle 4Q GAAP Operating Income Was $5.1 B >ORCL

11 de jun. de 2025, 20:08 UTC

Ganhos

Oracle 4Q Remaining Performance Obligations $138 B >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Rev $15.9B >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Hardware Revenue $850M >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Net $3.4B >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Services Revenue $1.35B >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Adj EPS $1.70 >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Cloud License and On-Premise License Revenue $2.01B >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q EPS $1.19 >ORCL

11 de jun. de 2025, 20:05 UTC

Ganhos

Oracle 4Q Cloud Services and License Support Revenue $11.7B >ORCL

11 de jun. de 2025, 19:00 UTC

Conversa de Mercado

Oil Futures Soar on Raft of Supportive News -- Market Talk

11 de jun. de 2025, 18:55 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

11 de jun. de 2025, 18:49 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 de jun. de 2025, 18:22 UTC

Conversa de Mercado

Gold Flat After Tentative U.S.-China Trade Deal -- Market Talk

11 de jun. de 2025, 18:19 UTC

Conversa de Mercado

UnitedHealth Seen on Longer Road to Recovery -- Market Talk

11 de jun. de 2025, 18:08 UTC

Conversa de Mercado
Ganhos

Vera Bradley Leans on Retail Partnerships to Drive Engagement -- Market Talk

Comparação entre Pares

Variação de preço

Axsome Therapeutics Inc Previsão

Preço-alvo

By TipRanks

63.56% parte superior

Previsão para 12 meses

Média 179.77 USD  63.56%

Máximo 210 USD

Mínimo 148 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Axsome Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

16

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

107.24 / 112.29Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

50 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.